Funding momentum POP Biotechnologies has ongoing and recently expanded external funding from CEPI totaling up to 9.7M to advance the SNAP protein vaccine platform into a Phase I trial, signaling strong credibility and potential for collaboration or co-development opportunities with public health and vaccine-focused partners.

Clinical expansion Recent news confirms active phase development across multiple programs including a shingles vaccine in collaboration with EuBiologics and a SNAP platform moving toward Phase I in New York, creating near-term engagement windows with CROs, contract manufacturers, and prospective licensees.

Focus on nanotech vaccines POP leverages porphyrin-phospholipid liposome technology for next-generation vaccines and therapeutics, a unique platform that could attract interest from large biotech and pharma seeking novel adjuvant or delivery systems to enhance antigen presentation and immune response.

grants and partnerships NIH support for a mosaic active immunotherapy and STTR funding demonstrates a track record of government-funded collaboration; this suggests potential for new grant-aligned partnerships, joint development ventures, and opportunities to position POP as a partner of choice for government or academic collaborations.

Small team, adaptable With a compact headcount (2-10 employees) and a diversified tech stack, POP appears agile and capable of rapid scoping and pilots; this indicates potential for quick pilot programs, tiered collaborations, or co-development trials with clinical and research partners seeking nimble partners.